10Jan/13

Phase III data in The Lancet show significant benefit of Novartis drug … – International Business Times (press release)

Phase III data in The Lancet show significant benefit of Novartis drug
International Business Times (press release)
10, 2013 /PRNewswire/ — Data published today in The Lancet showed that patients on Afinitor® (everolimus) tablets with non-cancerous kidney tumors known as renal angiomyolipomas associated with tuberous sclerosis complex (TSC) experienced a

and more »